| Literature DB >> 31935240 |
Rivka R Lilian1, Kate Rees1,2, James A McIntyre1,2, Helen E Struthers1,3, Remco P H Peters1,4,5.
Abstract
Same-day initiation (SDI) of antiretroviral therapy (ART) has been recommended to improve ART programme outcomes in South Africa since August 2017. This study assessed implementation of SDI over time in two South African districts, describing the characteristics of same-day initiators and evaluating the impact of SDI on retention in ART care. Routine data were analysed for HIV-infected adults who were newly initiating ART in Johannesburg or Mopani Districts between October 2017 and June 2018. Characteristics of same-day ART initiators were compared to later initiators, and losses to follow-up (LTFU) to six months were assessed using Kaplan Meier survival analysis and multivariate logistic regression. The dataset comprised 32 290 records (29 964 from Johannesburg and 2 326 from Mopani). The overall rate of SDI was 40.4% (n = 13 038), increasing from 30.3% in October 2017 to 54.2% in June 2018. Same-day ART initiators were younger, more likely to be female and presented with less advanced clinical disease than those initiating treatment at later times following diagnosis (p<0.001 for all). SDI was associated with disengagement from care: LTFU was 30.1% in the SDI group compared to 22.4%, 19.8% and 21.9% among clients initiating ART 1-7 days, 8-21 days and ≥22 days after HIV diagnosis, respectively (p<0.001). LTFU was significantly more likely among clients in Johannesburg versus Mopani (adjusted odds ratio (aOR) = 1.43, p<0.001) and among same-day versus later initiators (aOR = 1.45, p<0.001), while increasing age reduced LTFU (aOR = 0.97, p<0.001). In conclusion, SDI has increased over time as per national guidelines, but there is serious concern regarding the reduced rate of retention among same-day initiators. Nevertheless, SDI may result in a net programmatic benefit provided that interventions are implemented to support client readiness for treatment and ongoing engagement in ART care, particularly among younger adults in large ART programmes such as Johannesburg.Entities:
Year: 2020 PMID: 31935240 PMCID: PMC6959580 DOI: 10.1371/journal.pone.0227572
Source DB: PubMed Journal: PLoS One ISSN: 1932-6203 Impact factor: 3.240
Fig 1Trends in same-day antiretroviral therapy initiation over time.
(ART, antiretroviral therapy).
Baseline characteristics of clients initiating antiretroviral therapy by time from HIV diagnosis to treatment initiation.
| Same-day | 1–7 days | 8–21 days | 22+ days | P-value | |
|---|---|---|---|---|---|
| n | 13 038 | 7 261 | 6 534 | 5 457 | |
| Site | |||||
| Jhb District | 12 082 (92.7%) | 6 747 (92.9%) | 6 022 (92.2%) | 5 113 (93.7%) | |
| Mopani District | 956 (7.3%) | 514 (7.1%) | 512 (7.8%) | 344 (6.3%) | |
| Gender | |||||
| Male | 3 375 (25.9%) | 2 816 (38.8%) | 2 685 (41.1%) | 2 359 (43.2%) | |
| Female | 9 663 (74.1%) | 4 445 (61.2%) | 3 849 (58.9%) | 3 098 (56.8%) | |
| Age at ART start (years), median (range) | 31.9 (15.1–79.6) | 34.8 (15.3–75.7) | 35.8 (15.0–79.4) | 35.4 (15.0–78.2) | |
| Baseline CD4<100 | |||||
| Yes | 1 118 (14.1%) | 1 045 (19.0%) | 1 296 (25.3%) | 1 044 (26.9%) | |
| No | 6 805 (85.9%) | 4 446 (81.0%) | 3 820 (74.7%) | 2 836 (73.1%) | |
| WHO stage at ART start | |||||
| I/II | 11 673 (94.3%) | 6 344 (91.4%) | 5 227 (82.5%) | 3 893 (74.6%) | |
| III/IV | 702 (5.7%) | 596 (8.6%) | 1 110 (17.5%) | 1 329 (25.5%) | |
| Pregnant at ART start (females 15–50 years) | |||||
| Yes | 4 601 (50.0%) | 439 (10.8%) | 165 (4.8%) | 265 (9.5%) | |
| No | 4 608 (50.0%) | 3 611 (89.2%) | 3 256 (95.2%) | 2 530 (90.5%) |
ART, antiretroviral therapy; HIV, human immunodeficiency virus; Jhb, Johannesburg; WHO, World Health Organization
Data are n (%) unless otherwise indicated. Total value differs between variables because of missing data.
Statistically significant differences are shown in bold.
a Same-day, 1–7 day, 8–21 day and 22+ day initiations represent 40.4%, 22.5%, 20.2% and 16.9% of the study sample, respectively.
Programme outcomes by time from HIV diagnosis to initiation of antiretroviral therapy.
| Same-day | 1–7 days | 8–21 days | 22+ days | P-value | |
|---|---|---|---|---|---|
| n | 13 038 | 7 261 | 6 534 | 5 457 | |
| Programme outcomes | |||||
| Active | 8 399 (64.4%) | 5 276 (72.7%) | 4 860 (74.4%) | 3 976 (72.9%) | |
| LTFU | 3 804 (29.2%) | 1 586 (21.8%) | 1 254 (19.2%) | 1 162 (21.3%) | |
| Died | 42 (0.3%) | 37 (0.5%) | 48 (0.7%) | 78 (1.4%) | |
| TMO | 793 (6.1%) | 362 (5.0%) | 372 (5.7%) | 241 (4.4%) |
HIV, human immunodeficiency virus; LTFU, lost to follow-up; TMO, transferred or moved out
Data are n (%). Statistically significant differences are shown in bold.
a χ2 test for trend across time to ART initiation groups.
Fig 2Kaplan-Meier survival curve of LTFU by time from HIV diagnosis to antiretroviral therapy initiation.
(p = Peto-Peto test for equality of survivor functions. ART, antiretroviral therapy; HIV, human immunodeficiency virus; LTFU, loss to follow-up).
Characteristics of clients lost to follow-up from the ART programme by six months after treatment initiation.
| Unadjusted OR | Adjusted OR | |||||
|---|---|---|---|---|---|---|
| Active | LTFU | OR (95% CI) | P-value | OR (95% CI) | P-value | |
| n | 22 511 | 7 806 | ||||
| Site | ||||||
| Jhb District | 20 776 (92.3%) | 7 391 (94.7%) | 1.49 (1.33–1.66) | 1.43 (1.27–1.60) | ||
| Mopani District | 1 735 (7.7%) | 415 (5.3%) | Ref | Ref | ||
| Gender | ||||||
| Male | 8 122 (36.1%) | 2 411(30.9%) | 0.79 (0.75–0.84) | 0.97 (0.91–1.03) | 0.269 | |
| Female | 14 389 (63.9%) | 5 395 (69.1%) | Ref | Ref | ||
| Age at ART start (years), median (range) | 34.7 (15.0–79.6) | 31.5 (15.4–79.0) | 0.96 (0.96–0.97) | 0.97 (0.96–0.97) | ||
| Baseline CD4<100 | ||||||
| Yes | 3 245 (19.9%) | 910 (18.8%) | 0.93 (0.86–1.01) | 0.073 | - | - |
| No | 13 028 (80.1%) | 3 937 (81.2%) | Ref | |||
| WHO stage at ART start | ||||||
| I/II | 18 969 (88.0%) | 6 627 (89.3%) | 1.14 (1.05–1.24) | 0.92 (0.85–1.01) | 0.073 | |
| III/IV | 2 600(12.1%) | 797 (10.7%) | Ref | Ref | ||
| Same-day ART initiation | ||||||
| Yes | 8 399 (37.3%) | 3 804 (48.7%) | 1.60 (1.52–1.68) | 1.45 (1.37–1.53) | ||
| No | 14 112 (62.7%) | 4 002 (51.3%) | Ref | Ref | ||
ART, antiretroviral therapy; CI, confidence interval; Jhb, Johannesburg; LTFU, lost to follow-up; OR, odds ratio; Ref, reference; WHO, World Health Organization. Data are n (%) unless otherwise indicated. Total value differs between variables because of missing data. Statistically significant differences are shown in bold.
a Multivariate logistic regression adjusting for site, gender, age, WHO clinical stage and same-day ART initiation.